Ezra Cohen Highlights Sequential SBRT and Anti-PD1 Strategy in Lung Cancer
Ezra Cohen, Chief Medical Officer of Oncology at Tempus Labs, shared a post on LinkedIn:
“SBRT and anti-PD1, administered sequentially rather than concomitantly, appear to active anti-tumor immune responses. This strategy can be applied broadly and should be in curative settings.”
Title: Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer
Authors: Justin Huang, Willemijn S. M. E. Theelen, Zineb Belcaid, Mimi Najjar, Daphne van der Geest, Dipika Singh, Christopher Cherry, Archana Balan, James R. White, Jaime Wehr, Rachel Karchin, Noushin Niknafs, Michel M. van den Heuvel, Victor E. Velculescu, Kellie N. Smith, Paul Baas, Valsamo Anagnostou
Read The Full Article at Nature Cancer Link.
More posts featuring Lung Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023